Windtree Therapeutics, Inc.
WINT
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.25% | -12.66% | -10.38% | -11.68% | -14.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.87% | 34.19% | 41.41% | 62.15% | 67.10% |
| Operating Income | 33.87% | -34.19% | -41.41% | -62.15% | -67.10% |
| Income Before Tax | -35.24% | -176.57% | 91.16% | 63.21% | 57.13% |
| Income Tax Expenses | -201.93% | -205.26% | -- | 105.19% | 122.75% |
| Earnings from Continuing Operations | -28.76% | -169.27% | 91.19% | 60.90% | 53.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.76% | -169.27% | 91.19% | 60.90% | 53.46% |
| EBIT | 33.87% | -34.19% | -41.41% | -62.15% | -67.10% |
| EBITDA | 34.06% | -34.18% | -41.43% | -62.29% | -67.57% |
| EPS Basic | 79.09% | -- | -- | -- | -- |
| Normalized Basic EPS | 85.19% | -- | -- | -- | -- |
| EPS Diluted | 79.09% | -- | -- | -- | -- |
| Normalized Diluted EPS | 85.19% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 53,425.22% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 53,425.22% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |